An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects

British Journal of Clinical Pharmacology

Volumn 72, Issue 6, 2011, Pages 921-931

  Round, Patrick ^a   Priestley, Anthony ^b   Robinson, Jan ^a  

^a Xention Ltd   (United Kingdom)

^b LCG Bioscience   (United Kingdom)

Author keywords

Overactive bladder; TRPV1 antagonist; XEN D0501

Indexed keywords

UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST; XEN D 0501;

ABNORMAL DREAMING; ADULT; AGED; ARTICLE; BURNING SENSATION; CONTROLLED STUDY; CORE TEMPERATURE; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRY THROAT; DYSGEUSIA; ERYTHEMA; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; HYPERTHERMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NIGHT SWEAT; NORMAL HUMAN; NOSE CONGESTION; OPEN STUDY; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; BODY TEMPERATURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; TRPV CATION CHANNELS; YOUNG ADULT;

EID: 80855148142     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04040.x     Document Type: Article

References (29)

1. Alexander SPH, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 2009; 158 (Suppl. 1): S1-254.
2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
3. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002; 60 (Suppl. 1): 7-12.
4. Abrams P, Jackson S, Mattiasson A, Krishnan K, Haendler L. A randomized, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia. Proceedings of the International Continence Society 26th Annual Meeting. 1996: 276-7.
5. Jonas U, Hofner K, Madersbacher H. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997; 15: 144-51.
6. Chapple CR, Arano P, Bosch JLHR, De Ridder D, Kramer AEJL, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. Br J Urol 2003; 93: 71-7.
7. Cardozo L, Chapple CR, Toozs-Hobson P, Grosse-Freese M, Bulitta M, Lehmacher W, Strosser W, Ballering-Bruhl B, Schafer M. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 2000; 85: 659-64.
8. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6.
9. Stewart WF, Corey R, Herzog AR, Wein A, Norton PA, Payne C, Versi E, on behalf of the NO-BLE Program Research Team. Prevalence of overactive bladder in women: results from the Noble Program. Int Urogynecol J 2001; 12 (Suppl. 3): S66.
10. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 1999; 50: 159-211.
11. de Groat WC, Yoshimura N. Changes in afferent activity after spinal cord injury. Neurourol Urodyn 2010; 29: 63-76.
12. Geirsson G, Fall M, Sullivan L. Clinical and urodynamic effects of intravesical capsaicin treatment in patients with chronic traumatic spinal detrusor hyperreflexia. J Urol 1995; 154: 1825-9.
13. Lazzeri M, Beneforti P, Benaim G, Maggi CA, Lecci A, Turini D. Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. J Urol 1996; 156: 947-52.
14. De Seze M, Wiart L, Joseph PA, Dosque JP, Mazaux JM, Barat M. Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions. Neurourol Urodyn 1998; 17: 513-23.
15. Lazzeri M, Spinelli M, Zanollo A, Turini D. Intravesical vanilloids and neurogenic incontinence: ten years experience. Urol Int 2004; 72: 145-9.
16. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998; 21: 531-43.
17. Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999; 162: 3-11.
18. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-24.
19. Gavva NR, Bannon AW, Hovland DN, Lehto SG, Klionsky L, Surapaneni S, Immke DC, Henley C, Arik L, Bak A, Davis J, Ernst N, Hever G, Kuang R, Shi L, Tamir R, Wang J, Wang W, Zajic G, Shu D, Norman MH, Louis J-C, Magal E, Tranor JS. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther 2007; 323: 128-37.
20. FDA Guidance for Industry. Food-effect bioavailability and fed bioequivalence studies. December 2002.
21. Byrne C, Lim CL. The ingestible telemetric body core temperature sensor: a review of validity and exercise applications. Br J Sports Med 2007; 41: 126-33.
22. McKenzie JE, Osgood DW. Validation of a new telemetric core temperature monitor. International Thermal Physiology Symposium: Physiology and Pharmacology of Temperature Regulation, October-December 2004. J Thermal Biol 2004; 29: 605-11.
23. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000; 288: 306-13.
24. Gavva NR, Bannon AW, Surapaneni S, Hovland DN Jr, Lehto SG, Gore A, Juan T, Deng H, Han B, Klionsky L, Kuang R, Le A, Tamir R, Wang J, Youngblood B, Zhu D, Norman MH, Magal E, Treanor JS, Louis J-C. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J Neurosci 2007; 27: 3366-74.
25. Steiner AA, Turek VF, Almeida MC, Burmeister JJ, Oliveira DL, Roberts JL, Bannon AW, Norman MH, Louis J-C, Treanor JJS, Gavva NR, Romanovsky AA. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. J Neurosci 2007; 27: 7459-68.
26. Gavva NR, Treanor JJS, Garami A, Fang L, Surapaneni S, Akrami A, Alvarez F, Bak A, Darling M, Gore A, Jang GR, Kesslak JP, Ni L, Norman MH, Palluconi G, Rose MJ, Salfi M, Tan E, Romanovsky AA, Banfield C, Davar G. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008; 136: 202-10.
27. Garami A, Shimansky YP, Pakai E, Oliveira DL, Gavva NR, Romanovsky AA. Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia. J Neurosci 2010; 30: 1435-40.
28. Watabiki T, Kiso T, Kuramochi T, Yonezawa K, Tsuji N, Kohara A, Kakimoto S, Aoki T, Matuoka N. Amelioration of neuropathic pain by novel TRPV1 antagonist (AS1928370) in rats without hypothermic effect. J Pharmacol Exp Ther 2011; 336: 743-50.
29. Romanovsky AA, Almeida MC, Garami A, Steiner AA, Norman MH, Morrison SF, Nakamura K, Burmeister JJ, Nucci TB. The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not. Pharmacol Rev 2009; 61: 228-61.